Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Margherita Rimini,Mara Persano,Toshifumi Tada,Goki Suda,Shigeo Shimose,Masatoshi Kudo,Jaekyung Cheon,Fabian Finkelmeier,Ho Yeong Lim,José Presa Ramos,Gianluca Masi,Changhoon Yoo,Sara Lonardi,Bernardo Stefanini,Takashi Kumada,Naoya Sakamoto,Hideki Iwamoto,Tomoko Aoki,Hong Jae Chon,Vera Himmelsbach,Margarida Montes,Caterina Vivaldi,Caterina Soldà,Atsushi Hiraoka,Takuya Sho,Takashi Niizeki,Naoshi Nishida,Christoph Steup,Masashi Hirooka,Kazuya Kariyama,Joji Tani,Masanori Atsukawa,Koichi Takaguchi,Ei Itobayashi,Shinya Fukunishi,Kunihiko Tsuji,Toru Ishikawa,Kazuto Tajiri,Hironori Ochi,Satoshi Yasuda,Hidenori Toyoda,Chikara Ogawa,Takashi Nishimura,Takeshi Hatanaka,Satoru Kakizaki,Noritomo Shimada,Kazuhito Kawata,Fujimasa Tada,Hideko Ohama,Kazuhiro Nouso,Asahiro Morishita,Akemi Tsutsui,Takuya Nagano,Norio Itokawa,Tomomi Okubo,Taeang Arai,Michitaka Imai,Hisashi Kosaka,Atsushi Naganuma,Yohei Koizumi,Shinichiro Nakamura,Masaki Kaibori,Hiroko Iijima,Yoichi Hiasa,Valentina Burgio,Angelo Della Corte,Francesca Ratti,Francesco De Cobelli,Luca Aldrighetti,Mario Scartozzi,Stefano Cascinu,Andrea Casadei-Gardini
DOI: https://doi.org/10.1159/000528818
2023-01-20
Oncology
Abstract:Introduction: The prognostic nutritional index (PNI) is a multiparametric score introduced by Onodera based on the blood levels of lymphocytes and albumin in patients with gastrointestinal neoplasms. Regarding hepatocellular carcinoma (HCC), its prognostic role has been demonstrated in patients treated with sorafenib and lenvatinib. The aim of this real-world study is to investigate the association between clinical outcomes and PNI in patients being treated with atezolizumab plus bevacizumab. Methods: The overall cohort of this multicentric study included 871 consecutive HCC patients from 4 countries treated with atezolizumab plus bevacizumab in first-line therapy. The PNI was calculated as follows: 10 × serum albumin concentration (g/dL) + 0.005 × peripheral lymphocyte count (number/mm3). Results: For only 773 patients, data regarding lymphocyte counts and albumin levels were available, so only these patients were included in the final analysis. The cut-off point of the PNI was determined to be 41 by receiver operating characteristic (ROC) analysis. 268 patients (34.7%) were categorized as the PNI-low group, while the remaining 505 (65.3%) patients as the PNI-high group. At the univariate analysis, high PNI was associated with longer overall survival (OS) (22.5 vs. 10.1 months, HR 0.34, p < 0.01) and progression-free survival (PFS) (8.7 vs. 5.8 months, HR 0.63, p < 0.01) compared to patients with low PNI. At the multivariate analysis, high versus low PNI resulted as an independent prognostic factor for OS (HR 0.49 , p < 0.01) and PFS (HR 0.82, p = 0.01). There was no difference in objective response rate (ORR) between the two groups (high 26.1% vs. low 19.8%, p = 0.09), while disease control rate (DCR) was significantly higher in the PNI-high group (76.8% vs. 66.4%, p = 0.01). Conclusion: PNI is an independent prognostic factor for OS and PFS in HCC patients on first-line treatment with atezolizumab plus bevacizumab.
oncology